Hormone-based therapies including GLP-1 agonists, amylin analogs, and ghrelin modulators represent the next generation of drugs for obesity and diabetes, exploiting the body's own appetite and glucose regulatory systems.
Key findingHormone-based fuel metabolism drugs span GLP-1 agonists (semaglutide class), amylin analogs (pramlintide), PYY analogs, and ghrelin modulators for int
What the researchers found
Hormone-based fuel metabolism drugs span GLP-1 agonists (semaglutide class), amylin analogs (pramlintide), PYY analogs, and ghrelin modulators for integrated obesity/diabetes treatment — exploiting endogenous regulatory peptide systems for superior metabolic control.
Why it matters
Relevant for glp-1, neuropeptides, weight-loss, diabetes.
How the study worked
review study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Hormone-based therapies in the regulation of fuel metabolism and body weight.
Expert opinion on biological therapy, 8(11), 1733-47
Citation
Kesty, Nicole C; Roth, Jonathan D; Maggs, David. (2008). Hormone-based therapies in the regulation of fuel metabolism and body weight.. Expert opinion on biological therapy, 8(11), 1733-47. https://doi.org/10.1517/14712598.8.11.1733